The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
An improving pharmacy retail business helped CVS Health beat analysts' third-quarter earnings and revenue expectations. The company also said Tuesday it anticipates its acquisition of health insurer Aetna to close before Thanksgiving.
Shares of the company rose about 2 percent.
Here's what the company reported compared with what Wall Street was expecting, based on a survey of analysts by Refinitiv:
CVS reported fiscal third-quarter net income of $1.39 billion, or $1.36 per share, up from $1.29 billion, or $1.26 per share a year earlier. Excluding items, CVS earned $1.73 per share, above the $1.71 per share expected by analysts surveyed by Refinitiv.
Revenue rose 2.4 percent to $47.3 billion, surpassing expectations of $47.2 billion. For the business unit that includes CVS' retail pharmacy operations, revenue increased to $20.86 billion, up nearly 7 percent from the $19.59 billion in the year-ago quarter, driven by an 8.4 percent surge in pharmacy revenue.
The company's retail business showed signs of improvement, with revenue from the so-called front store, which includes products like makeup and vitamins, increasing 2 percent from last year. Same-store sales, a closely watched metric, were up 0.8 percent. While the trends improved, they were up against easy comparisons.
"While this is a shallow gain, it is most definitely a step in the right direction," said Neil Saunders, managing director of GlobalData Retail. "However, our outlook on the retail side remains cautious, and we are split as to whether this represents the start of a new upside for CVS' retail operation, or whether it is just an anomaly."
Like other drugstores, CVS is searching for ways to lure shoppers who are increasingly shopping online. One solution might be CarePass, a membership program CVS is piloting in Boston.
To shake up its business model, CVS is in the midst of acquiring health insurer Aetna for roughly $69 billion. CVS received preliminary approval from the Department of Justice in October to move forward with the deal. The company still needs a handful of states to clear the deal, including New York, where state officials are considering blocking parts of it.
CVS on Tuesday said it has received approval from 23 of the 28 states it has filed with and is "well down the line" with the remaining five. The company expects to close the deal before Thanksgiving.
The company backed its full-year forecast of adjusted earnings of $6.98 to $7.08 per share. Analysts polled by Refinitiv expect $7.04 per share.